celiprolol has been researched along with Atherogenesis in 1 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, T | 1 |
| Juliet, PA | 1 |
| Miyazaki-Akita, A | 1 |
| Funami, J | 1 |
| Matsui-Hirai, H | 1 |
| Fukatsu, A | 1 |
| Iguchi, A | 1 |
1 other study available for celiprolol and Atherogenesis
| Article | Year |
|---|---|
beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Agonists; Animals; Aorta, Abdomin | 2007 |